Clinical event adjudication: Heart failure requiring hospitalization
For the list of clinical event adjudication definitions, click here
This chapter presents heart failure requiring hospitalization definitions used in the Clinical Event Committee adjudication processes. These definitions are current as of 3/26/10.

# Heart failure requiring hospitalization
Heart failure (HF) requiring hospitalization is defined as an event that meets the following criteria:
- Requires hospitalization defined as an admission to an inpatient unit or a visit to an emergency department that results in at least a 24- hour stay (or a date change if the time ofadmission/discharge is not available).*For this endpoint in any given clinical trial, there should be some flexibility in the required duration of stay, depending on the population and the adverse event profile of the drug to be studied.  For example, a clinical trial studying patients with NYHA Class III/IV heart failure may not wish to capture hospitalizations less than 24 hours in duration, because this population may have frequent hospital visits requiring short-term therapy.  On the contrary, clinical trials in patients with NYHA Class I/II heart failure may wish to capture shorter hospitalizations that may be predictive of subsequent decompensation.AND
- Clinical symptoms of heart failure, including at least one of the following:New or worsening
dyspnea
-rthopnea
paroxysmal nocturnal dyspnea
increasing fatigue/worsening exercise toleranceAND
- dyspnea
- orthopnea
- paroxysmal nocturnal dyspnea
- increasing fatigue/worsening exercise toleranceAND
- Physical signs of heart failure, including at least two of the following:
edema (greater than 2+ lower extremity)
pulmonary crackles greater than basilar (pulmonary edema must be sufficient to cause tachypnea and distress not occurring in the context of an acute myocardial infarction or as the consequence of an arrhythmia occurring in the absence of worsening heart failure)
jugular venous distension
tachypnea (respiratory rate > 20 breaths/minute)
rapid weight gain
S3 gallop
increasing abdominal distension or ascites
hepatojugular reflux
radiological evidence of worsening heart failure
A right heart catheterization within 24 hours of admission showing a pulmonary capillary wedge pressure (pulmonary artery occlusion pressure)  18 mm Hg or a cardiac output < 2.2 L/min/m2NOTE: Biomarker results (e.g., brain natriuretic peptide (BNP)) consistent with congestive heart failure will be supportive of this diagnosis, but the elevation in BNP cannot be due to other conditions such as cor pulmonale, pulmonary embolus, primary pulmonary hypertension, or congenital heart disease.  Increasing levels of BNP, although not exceeding the ULN, may also be supportive of the diagnosis of congestive heart failure in selected cases (e.g. morbid obesity).AND
- edema (greater than 2+ lower extremity)
- pulmonary crackles greater than basilar (pulmonary edema must be sufficient to cause tachypnea and distress not occurring in the context of an acute myocardial infarction or as the consequence of an arrhythmia occurring in the absence of worsening heart failure)
- jugular venous distension
- tachypnea (respiratory rate > 20 breaths/minute)
- rapid weight gain
- S3 gallop
- increasing abdominal distension or ascites
- hepatojugular reflux
- radiological evidence of worsening heart failure
- A right heart catheterization within 24 hours of admission showing a pulmonary capillary wedge pressure (pulmonary artery occlusion pressure)  18 mm Hg or a cardiac output < 2.2 L/min/m2NOTE: Biomarker results (e.g., brain natriuretic peptide (BNP)) consistent with congestive heart failure will be supportive of this diagnosis, but the elevation in BNP cannot be due to other conditions such as cor pulmonale, pulmonary embolus, primary pulmonary hypertension, or congenital heart disease.  Increasing levels of BNP, although not exceeding the ULN, may also be supportive of the diagnosis of congestive heart failure in selected cases (e.g. morbid obesity).AND
- Need for additional/increased therapy
Initiation of, or an increase in, treatment directed at heart failure or occurring in a patient already receiving maximal therapy for heart failure and including at least one of the following:
Initiation of or a significant augmentation in oral therapy for the treatment of congestive heart failure
Initiation of intravenous diuretic, inotrope, or vasodilator therapy
Uptitration of intravenous therapy, if already on therapy
Initiation of mechanical or surgical intervention (mechanical circulatory support, heart transplantation or ventricular pacing to improve cardiac function), or the use of ultrafiltration, hemofiltration, or dialysis that is specifically directed at treatment of heart failure.AND
- Initiation of, or an increase in, treatment directed at heart failure or occurring in a patient already receiving maximal therapy for heart failure and including at least one of the following:
Initiation of or a significant augmentation in oral therapy for the treatment of congestive heart failure
Initiation of intravenous diuretic, inotrope, or vasodilator therapy
Uptitration of intravenous therapy, if already on therapy
Initiation of mechanical or surgical intervention (mechanical circulatory support, heart transplantation or ventricular pacing to improve cardiac function), or the use of ultrafiltration, hemofiltration, or dialysis that is specifically directed at treatment of heart failure.AND
- Initiation of or a significant augmentation in oral therapy for the treatment of congestive heart failure
- Initiation of intravenous diuretic, inotrope, or vasodilator therapy
- Uptitration of intravenous therapy, if already on therapy
- Initiation of mechanical or surgical intervention (mechanical circulatory support, heart transplantation or ventricular pacing to improve cardiac function), or the use of ultrafiltration, hemofiltration, or dialysis that is specifically directed at treatment of heart failure.AND